Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Anocca

company

About

Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
€25M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Oct 23, 2014
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Anocca AB

Anocca provides services like biotechnology, immunotherapeutics, drug discovery, drug development, and immunology services.

The company does precise and efficient analysis of T-cell biology, which is required to deliver a variety of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, assisting the life sciences sector in developing a variety of therapies and vaccination strategies.

Anocca was established on October 23, 2014 by Reagan Jarvis in Södertälje, Vasternorrlands Lan.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€25M $47M
Anocca has raised a total of €25M $47M in funding over 2 rounds. Their latest funding was raised on Dec 21, 2022 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 21, 2022 Debt Financing €25M 1 European Investment Bank Detail
Jul 22, 2021 Series B $47M 5 Detail

Investors

Number of Lead Investors
Number of Investors
1
6
Anocca is funded by 6 investors. European Investment Bank and Harald Mix are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Debt Financing
Harald Mix Series B
Nidoco Series B
Ramsbury Invest AB Series B
Robert Andreen Series B
Swedbank Robur’s Ny Teknik Series B

Employee Profiles

Number of Employee Profiles
2
Anocca has 2 current employee profiles, including Executive Reagan Jarvis
Executive
Executive